Answers are grounded in this paper and cite their sources.
Randomized trial compares efficacy outcomes of acoramidis in transthyretin amyloid cardiomyopathy, indicating significant treatment potential.
Background: Acoramidis is an oral, highly selective transthyretin (TTR) stabilizer approved for transthyretin amyloid cardiomyopathy (ATTR-CM). This analysis compared efficacy outcomes over a 30-month period between acoramidis-treated patients from the Phase 3 Japan Study (NCT04622046) with propensity score (PS)-matched placebo patients from the global ATTRibute-CM trial (NCT03860935).
No takes yet. Share an insight, caveat, or question.
Tahara et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: